Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
144.4 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
19
19 articles ont été cités au moins 19fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 306
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
68
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
32
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Cardiologique du Haut-Lévêque
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
2025ArticleJournal of Clinical Oncology
Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prospective multicentre study
2024ArticleEBioMedicine
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study
2023ArticleJNCI Cancer Spectrum
OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel
2023ArticleEuropean Journal of Endocrinology
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
2022ArticleJAMA oncology
Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients
2021ArticleSupportive Care in Cancer
Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study
2021ArticleClinics and Research in Hepatology and Gastroenterology
Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery
2021ArticleActa Oncologica
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL HAUT-LEVEQUE - CHU
AV DE MAGELLAN, 33604 PESSAC CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
European journal of radiology · 2013
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
PURPOSE Whether triplet chemotherapy is superior to doublet chemotherapy in advanced biliary tract cancer (BTC) is unknown. METHODS In this open-label, randomized phase II-III study, patients with locally advanced or metastatic BTC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (1:1) to receive oxaliplatin, irinotecan, and infusional fluorouracil (mFOLFIRINOX), or cisplatin and gemcitabine (CISGEM) for a maximum of 6 months. We report the results of the phase II part, where the primary end point was the 6-month progression-free survival (PFS) rate among the patients who received at least one dose of treatment (modified intention-to-treat population) according to Response Evaluation Criteria in Solid Tumors version 1.1 (statistical assumptions: 6-month PFS rate ≥ 59%, 73% expected). RESULTS A total of 191 patients (modified intention-to-treat population, 185: mFOLFIRINOX, 92; CISGEM, 93) were randomly assigned in 43 French centers. After a median follow-up of 21 months, the 6-month PFS rate was 44.6% (90% CI, 35.7 to 53.7) in the mFOLFIRINOX arm and 47.3% (90% CI, 38.4 to 56.3) in the CISGEM arm. Median PFS was 6.2 months (95% CI, 5.5 to 7.8) in the mFOLFIRINOX arm and 7.4 months (95% CI, 5.6 to 8.7) in the CISGEM arm. Median overall survival was 11.7 months (95% CI, 9.5 to 14.2) in the mFOLFIRINOX arm and 13.8 months (95% CI, 10.9 to 16.1) in the CISGEM arm. Adverse events ≥ grade 3 occurred in 72.8% of patients in the mFOLFIRINOX arm and 72.0% of patients in the CISGEM arm (toxic deaths: mFOLFIRINOX arm, two; CISGEM arm, one). CONCLUSION mFOLFIRINOX triplet chemotherapy did not meet the primary study end point. CISGEM doublet chemotherapy remains the first-line standard in advanced BTC.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Acta oncologica (Stockholm, Sweden) · 2021 · Journal Article
Terlizzi M, Buscail E, Boussari O, Adgié S, et al.
International journal of cancer · 2021 · Journal Article
Aparicio T, Svrcek M, Henriques J, Afchain P, et al.
Clinical nutrition (Edinburgh, Scotland) · 2020 · Clinical Study
Dolly A, Lecomte T, Bouché O, Borg C, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2019 · Clinical Trial, Phase I
Vendrely V, Lemanski C, Gnep K, Barbier E, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2019 · Journal Article
Pouypoudat C, Buscail E, Cossin S, Cassinotto C, et al.
Ultraschall in der Medizin (Stuttgart, Germany : 1980) · 2018 · Journal Article
Tranquart F, Dujardin PA, Bouché O, Marcus C, et al.
European journal of radiology · 2017 · Evaluation Study
Cassinotto C, Chong J, Zogopoulos G, Reinhold C, et al.
Annals of surgical oncology · 2015 · Journal Article
Pietrasz D, Marthey L, Wagner M, Blanc JF, et al.
Annals of surgical oncology · 2015 · Comparative Study
Luc G, Vendrely V, Terrebonne E, Chiche L, et al.
European journal of radiology · 2013 · Journal Article
Cassinotto C, Cortade J, Belleannée G, Lapuyade B, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2023 · Randomized Controlled Trial
Aparicio T, Bouché O, Etienne PL, Barbier E, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · Clinical Trial, Phase II
Phelip JM, Desrame J, Edeline J, Barbier E, et al.
Journal of neuro-oncology · 2025 · Journal Article
Randrian V, Portales F, Bouché O, Thezenas S, et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2019 · Journal Article
Rompteaux P, Gagnière J, Gornet JM, Coriat R, et al.
Fundamental & clinical pharmacology · 2013 · Comparative Study
Smith D, Terrebonne E, Rouyer M, Blanc JF, et al.
Journal of cachexia, sarcopenia and muscle · 2019 · Journal Article
Arrieta H, Astrugue C, Regueme S, Durrieu J, et al.
Fundamental & clinical pharmacology · 2017 · Journal Article
Gouverneur A, Rouyer M, Grelaud A, Robinson P, et al.
Clinics and research in hepatology and gastroenterology · 2011 · Clinical Trial, Phase II
Journal of cachexia, sarcopenia and muscle · 2019 · Journal Article
Arrieta H, Astrugue C, Regueme S, Durrieu J, et al.
Gastroenterologie clinique et biologique · 2008 · English Abstract
Laharie D, Terrebonne E, Vergniol J, Chanteloup E, et al.
Clinics and research in hepatology and gastroenterology · 2011 · Clinical Trial, Phase II
Fonck M, Brunet R, Becouarn Y, Legoux JL, et al.
Clinics and research in hepatology and gastroenterology · 2018 · Journal Article
Plante A, Baudin E, Do Cao C, Hentic O, et al.
Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study
Abstract Background Associations between polymorphisms of UDP-glucuronosyltransferases (UGTs) or efflux transporters (e.g., P-glycoprotein and MRP2) and different types of cancer have been described, whereas the role of
Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study
Abstract Background Associations between polymorphisms of UDP-glucuronosyltransferases (UGTs) or efflux transporters (e.g., P-glycoprotein and MRP2) and different types of cancer have been described, whereas the role of
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2021 · Clinical Trial, Phase III
Monteil J, Le Brun-Ly V, Cachin F, Zasadny X, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Clinical Trial, Phase II
Rinaldi Y, Pointet AL, Khemissa Akouz F, Le Malicot K, et al.
Journal of cachexia, sarcopenia and muscle · 2019 · Journal Article
Arrieta H, Astrugue C, Regueme S, Durrieu J, et al.
PloS one · 2014 · Journal Article
Bourdel-Marchasson I, Blanc-Bisson C, Doussau A, Germain C, et al.
Bulletin du cancer · 2012 · Clinical Trial, Phase II
Laval G, Rousselot H, Toussaint-Martel S, Mayer F, et al.
Clinics and research in hepatology and gastroenterology · 2011 · Clinical Trial, Phase II
Fonck M, Brunet R, Becouarn Y, Legoux JL, et al.
Fonck M, Brunet R, Becouarn Y, Legoux JL, et al.